SEC Filing Summary: Repro-Med Systems, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Repro-Med Systems, Inc., a smaller reporting company incorporated in New York. The report covers the three-month period ended May 31, 2010. The Company designs, manufactures, and markets medical devices, primarily the Freedom60 syringe infusion pump and the RES-Q-VAC emergency airway suction system.
Key Financial Metrics
| Metric | Q1 2010 (Ended May 31) | Q1 2009 (Ended May 31) |
|---|---|---|
| Net Sales | $982,942 | $813,129 |
| Net Operating Income | $136,039 | $98,822 |
| Net Income | $88,420 | $64,053 |
| Net Cash from Operating Activities | $288,983 | $97,344 |
| Cash and Cash Equivalents (Ending) | $1,054,416 | $581,249 |
| Total Debt (Current + Long-Term) | $652,857 | $689,966 |
| Working Capital | $2,022,788 | $1,983,597 |
Note: Gross Margin for Q1 2010 was approximately 63.1% ($619,554 Gross Profit / $982,942 Sales).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21% year-over-year, driven by a 25% increase in Freedom60 sales ($760,967 vs. $609,166) and a 9% increase in RES-Q-VAC sales.
- Profitability: Net income rose 38% to $88,420. Net operating income increased 37.7%.
- Expense Trends: Selling, General, and Administrative (SG&A) expenses increased 22.3% due to marketing efforts, trade shows, and hiring. Cost of Goods Sold (COGS) increased 16.3% in line with higher production volume.
- Debt Reduction: Total debt decreased by approximately $37,000. The Company fully paid off a vehicle loan in April 2010 and repaid a $100,000 demand loan to the President in June 2010 (subsequent to quarter end).
- Cash Flow: Operating cash flow nearly tripled to $288,983, primarily due to improved receivables collections and a reduction in deferred tax assets.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to meet financial needs for the next 12 months based on current capital and increasing sales. They anticipate continued growth in the subcutaneous immune globulin (IgG) market for the Freedom60, supported by a new 20% IgG drug solution.
- Government Grant: The Company received a $150,000 grant from the Trade Adjustment Assistance Program (50% match) for marketing and regulatory affairs. Approximately $55,000 in assistance remained available as of May 31, 2010.
- Risks: Key risks include dependence on Medicare reimbursement rates, FDA regulatory changes, competition from larger firms, and the success of new product development (specifically subcutaneous infusion sets).
- Unusual Items: The Company recorded $28,425 in "Forgiveness of Interest" income related to a loan from the President, where half of the accrued interest was forgiven.
- Contingencies: The Company has a contingent liability of approximately $10,000 for rework on a customer order, which has been provisioned for.
Investor Verification Checklist
- Verify the sustainability of the 21% revenue growth rate and the specific contribution of the Freedom60 product line.
- Confirm the status of the $100,000 loan repayment to the President and the accounting treatment of the forgiven interest.
- Monitor the utilization and remaining balance of the $55,000 Trade Adjustment Assistance grant.
- Assess the impact of potential changes in Medicare HCPCS coding (E0779) on reimbursement rates for the Freedom60.
- Review the $10,000 contingency provision for product rework to ensure no further costs are incurred.